From daily comfort to extended wear: why CooperVision’s Biofinity contacts stay popular

CooperCompanies’ Biofinity soft contact lenses target wearers who want all-day comfort and the option for extended wear, with a silicone hydrogel material and monthly replacement cycle. We look at what sets Biofinity apart in a crowded vision-care market.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 12:14 PM ET. Details in the imprint.

Biofinity, CooperVision’s flagship family of monthly soft contact lenses, sits at the center of CooperCompanies’ vision-care portfolio as a workhorse option for everyday wearers who want comfort, breathability and broad prescription coverage without stepping into premium daily disposables. The Biofinity line is built around a silicone hydrogel material designed for high oxygen transmission and approved in many markets for up to 6 nights and 7 days of extended wear, giving eye-care professionals flexibility to tailor wearing schedules. According to CooperVision, more than 100 million people worldwide already rely on its soft contact lenses, underscoring the strategic weight of Biofinity as a core recurring-revenue driver on the official Biofinity product page.

What Biofinity lenses offer monthly wearers

At its core, Biofinity is a monthly replacement silicone hydrogel lens made with CooperVision’s proprietary Aquaform Technology, a material chemistry that locks water into the lens and yields a naturally wettable surface without added surface treatments or wetting agents. The lens has a relatively high water content of around 48 percent and a Dk/t value (a measure of oxygen transmissibility) of approximately 160 for a -3.00 diopter lens, supporting all-day corneal oxygenation compared with many older hydrogel designs. For US patients, Biofinity spheres typically cover a power range from about -12.00 to +8.00 diopters, and the line extends into Biofinity Toric for astigmatism and Biofinity Multifocal for presbyopia, allowing eye-care practices to keep patients within a single material family as their visual needs change over time.

One practical reason Biofinity remains a staple in optometry offices is its balance of performance and cost in the midrange of the soft-lens market. As a reusable monthly lens, Biofinity usually comes in 6-pack boxes, supporting roughly a half-year of wear per eye when replaced on schedule, which often results in lower annual lens spend than many daily disposable options. Independent reviews from contact-lens specialists routinely highlight consistent comfort over the wearing month and relatively low rates of dehydration-related end-of-day dryness compared with older-generation hydrogels using separate surface coatings. Eye-care professionals also point to the lens’ slightly stiffer handling profile as a benefit for new wearers who may struggle with very thin daily disposable lenses during insertion and removal, particularly when learning lens hygiene routines.

Beyond the core spherical lens, CooperVision has grown Biofinity into a broader platform: Biofinity XR expands powers to address very high myopia and hyperopia, Biofinity Toric XR pushes cylinder and axis options for complex astigmatism, and Biofinity Multifocal offers multiple lens designs to support presbyopic patients who want to reduce dependence on reading glasses. In some markets, the Biofinity family also includes variants tailored to digital-device users with lens designs and prescriptions aimed at easing accommodative strain, reflecting how near work on screens has altered vision-care demand patterns. This modular approach turns Biofinity into an ecosystem, making it easier for optometrists to keep patients within a familiar brand and material as their refractive errors evolve, which in turn reinforces CooperVision’s recurring revenue from annual lens supplies.

From a regulatory and safety perspective, Biofinity lenses are cleared in major markets such as the United States and Europe as monthly replacement lenses with the option, subject to practitioner judgment, for extended wear up to several nights in select patients without significant ocular contraindications. That flexibility carries important caveats: overnight wear is associated with a higher relative risk of corneal complications compared with daily wear, and professional guidelines emphasize careful patient selection, hygiene, and follow-up visits. Biofinity’s high oxygen transmission and wettable material address some of the historical limitations of older extended-wear lenses, but adherent lens care and respecting replacement schedules remain central to maintaining ocular health. Many optometrists therefore continue to prescribe Biofinity primarily for daily wear with occasional overnight use for specific lifestyle needs, rather than continuous wear for the full approved duration.

CooperVision also positions Biofinity as a key part of its sustainability and practice-support messaging, even though monthly lenses inherently generate more plastic waste per lens than long-wear rigid gas permeable options but less packaging waste than daily disposables. The company runs recycling programs for contact lenses and blister packs in certain markets and publishes environmental impact materials for practitioners, framing monthly lenses like Biofinity as a compromise between convenience, comfort, and waste generation. At the same time, Biofinity’s consistent demand helps CooperCompanies invest in specialty products such as MiSight 1 day for myopia management, which targets a younger demographic, illustrating how high-volume flagship lines can indirectly fund category-expanding innovations elsewhere in the portfolio.

While CooperVision does not break out revenue for individual brands like Biofinity in its public filings, soft contact lenses remain the dominant contributor to CooperCompanies’ CooperVision segment, with monthly and two-week silicone hydrogel lenses representing a significant share of that mix. The company’s latest filings and presentations describe CooperVision as a global leader in soft contact lenses by revenue, with growth driven by silicone hydrogel adoption and specialty lenses for astigmatism and presbyopia as noted in CooperCompanies’ recent investor presentation. For investors tracking the broader narrative, Biofinity’s ongoing popularity with practitioners and patients is one indicator of how stable the company’s recurring contact-lens cash flows may be, even as new modalities like daily disposables and myopia-control products grow faster from a smaller base.

Sitting within this context, Biofinity illustrates CooperCompanies’ strategy of using a durable, midpriced flagship to anchor its vision-care offering while layering on specialty and premium lines above it. Shares of CooperCompanies (US21664P1039) traded on NASDAQ at $103.72 on 06/12/2026, reflecting how equity investors currently value the company’s mix of steady contact-lens demand and growth initiatives in both CooperVision and CooperSurgical based on NASDAQ trading data.

Biofinity contact lenses in brief: key facts

• Product: Biofinity (Biofinity family of monthly soft contact lenses)
• Manufacturer: CooperCompanies
• Category: Flagship/Bestseller monthly soft contact lenses
• Launch date: Mid-2000s (gradual rollout, varies by market)
• MSRP / Price: Typically midrange; US retail pricing often quoted per 6-pack box, varying by practice and online retailer
• Availability: Widely available via optometrists, ophthalmology practices and authorized online retailers in North America, Europe and other major markets
• Target audience: Soft contact-lens wearers needing spherical, toric or multifocal correction who prefer monthly replacement
• Key differentiator / USP: Silicone hydrogel material with Aquaform Technology for high oxygen transmission and all-day comfort, extended wear approval in many markets, and an extensive power and design range across the Biofinity family.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.